Keyphrases
AIDS/HIV
79%
Human Immunodeficiency Virus Type 1 (HIV-1)
42%
Quadrivalent Human Papillomavirus Vaccine
39%
High-risk Human Papillomavirus (HR-HPV)
34%
Antiretroviral Therapy
31%
AIDS Clinical Trials
29%
HIV Patients
26%
Transgender
25%
Pre-exposure Prophylaxis (PrEP)
24%
Phase II Trial
21%
Tenofovir Alafenamide
19%
HIV Pre-exposure Prophylaxis
19%
Clinical Trials
18%
Hispanic
18%
Papillomavirus Infections
18%
HIV Infection
16%
High-grade Squamous Intraepithelial Lesion
16%
Seroconversion
16%
African American
16%
Confidence Interval
16%
United States
15%
People Living with HIV (PLHIV)
15%
HPV16
14%
Anal Cytology
14%
Emtricitabine
14%
Vaccine Types
14%
Anogenital
14%
Human Papillomavirus Vaccine
13%
Efavirenz
13%
CD4 Count
13%
Viral Suppression
13%
Tenofovir Disoproxil Fumarate
12%
Group Communication Protocol
12%
Randomized Placebo-controlled Trial
12%
Latinx
12%
Quadrivalent
11%
Cervical Dysplasia
11%
Men Who Have Sex with Men
11%
Randomized Double-blind
11%
Cardiovascular Disease
11%
Immune Activation
11%
Human Immunodeficiency Virus Testing
11%
Mobile Health Intervention
9%
Supporting Patients
9%
Human Papillomavirus Virus
9%
Placebo-controlled
9%
Sustained Response
9%
Disease Pathogenesis
9%
Long-term Safety
9%
Gender-affirming Hormone Therapy
9%
Medicine and Dentistry
Human Immunodeficiency Virus
100%
Clinical Trial
29%
Placebo
21%
Disease
19%
Wart Virus Vaccine
19%
Wart Virus
19%
Human Immunodeficiency Virus Infection
18%
Cytotechnology
17%
Papillomavirus Infection
16%
Cardiovascular Disease
13%
Antiretroviral Therapy
13%
Uterine Cervix Dysplasia
12%
Infection
10%
Anal Cancer
9%
Oxidized Low Density Lipoprotein
9%
Tenofovir Alafenamide
9%
Tenofovir Disoproxil
9%
Cervical Cancer Screening
9%
Cardiovascular Disease Prevention
9%
Pre-Exposure Prophylaxis
9%
Weil's Disease
9%
Emtricitabine
9%
Environmental Exposure
9%
Patient Counseling
9%
Leptospira
9%
Papillomatosis
9%
Endothelial Dysfunction
9%
Fosamprenavir
9%
Amprenavir
9%
Cord Blood
9%
Pharmacokinetics
9%
Steady State
9%
Ritonavir
9%
Cancer Therapy
9%
Immunity
9%
HIV Test
9%
Human Immunodeficiency Virus Disease Prevention
9%
Cancer Screening
7%
Seroconversion
6%
Dysplasia
6%
Single Nucleotide Polymorphism
6%
Biopsy Technique
6%
Prevalence
6%
Transgender
6%
Vaccine
5%
Anoscopy
5%